Manipulation does not stop beyond OTC yes its volatile but until lympro revenue is coming in they belong on the pinks imho. I don't want to uplist with no lympro cash whether through revenue or BP and a traditional partnership. A reverse split to the NASDAQ from where we are no thanks. I want to uplist with the chances of dilution greatly decreased. MANF data, Elto trials, etc are not gonna do it the market knows the value is too far in the future.